Rice Hall James & Associates LLC raised its position in shares of scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 59.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 989,635 shares of the company's stock after acquiring an additional 367,970 shares during the quarter. Rice Hall James & Associates LLC owned approximately 1.98% of scPharmaceuticals worth $3,503,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in SCPH. BNP Paribas Financial Markets boosted its stake in scPharmaceuticals by 116.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company's stock worth $26,000 after purchasing an additional 3,101 shares during the last quarter. Virtu Financial LLC acquired a new position in scPharmaceuticals during the third quarter worth about $46,000. Legato Capital Management LLC purchased a new stake in scPharmaceuticals during the 4th quarter valued at about $37,000. China Universal Asset Management Co. Ltd. acquired a new stake in scPharmaceuticals in the 4th quarter valued at about $38,000. Finally, The Manufacturers Life Insurance Company purchased a new position in scPharmaceuticals in the 3rd quarter worth approximately $57,000. 89.52% of the stock is owned by institutional investors and hedge funds.
scPharmaceuticals Trading Down 3.3 %
Shares of NASDAQ SCPH traded down $0.11 during midday trading on Friday, reaching $3.25. 403,526 shares of the stock were exchanged, compared to its average volume of 247,628. The stock has a market capitalization of $162.63 million, a P/E ratio of -1.71 and a beta of 0.11. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08. The company has a 50 day simple moving average of $3.40 and a 200 day simple moving average of $4.04. scPharmaceuticals Inc. has a twelve month low of $3.08 and a twelve month high of $6.54.
Wall Street Analysts Forecast Growth
Several research firms recently commented on SCPH. Craig Hallum cut their price target on scPharmaceuticals from $16.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, November 14th. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 target price on shares of scPharmaceuticals in a research note on Thursday, November 14th.
Read Our Latest Research Report on SCPH
scPharmaceuticals Company Profile
(
Free Report)
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.
Featured Stories
Before you consider scPharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and scPharmaceuticals wasn't on the list.
While scPharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
